| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 07/31/2003 | WO2003061765A1 Method of prophylaxis against large myocardial infarctions |
| 07/31/2003 | WO2003061696A2 Systems and methods for photodynamic therapy |
| 07/31/2003 | WO2003061691A1 Orodispersible pharmaceutical composition comprising perindopril |
| 07/31/2003 | WO2003061689A1 Thrombin derived peptides for promoting cardiac tissue repair |
| 07/31/2003 | WO2003061687A1 High-concentration preparation of soluble thrombomodulin |
| 07/31/2003 | WO2003061685A1 Therapeutic application of g-csf, gm-csf and scf |
| 07/31/2003 | WO2003061667A1 Pharmaceutically acceptable phosphate-glycerol carrying bodies |
| 07/31/2003 | WO2003061666A1 Phospholipid bodies and use thereof in the treatment of inflammatory and autoimmune diseases |
| 07/31/2003 | WO2003061662A1 Orodispersible pharmaceutical composition comprising ivabradine |
| 07/31/2003 | WO2003061659A1 Treating stress response with chemokine receptor ccr5 modulators |
| 07/31/2003 | WO2003061655A1 2-aminothiazole allosteric enhancers of a1 adenosine receptors |
| 07/31/2003 | WO2003061653A1 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
| 07/31/2003 | WO2003061652A1 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
| 07/31/2003 | WO2003061648A1 Use of cholinesterase antagonists to treat insulin resistance |
| 07/31/2003 | WO2003061642A1 Use of ambroxol in the treatment of chronic pains, cerebral excitotoxicity-related disorders and cardiac arrhythmias |
| 07/31/2003 | WO2003061634A1 Sustained release pharmaceutical composition |
| 07/31/2003 | WO2003061626A1 Polymeric gel system for the controlled delivery of codrugs |
| 07/31/2003 | WO2003061620A2 Peptide-carrying bodies for immune response |
| 07/31/2003 | WO2003061587A2 USE OF TGF-β ANTAGONISTS TO TREAT OR TO PREVENT CHRONIC TRANSPLANT REJECTION |
| 07/31/2003 | WO2003061566A2 Anti-cancer combination and use thereof |
| 07/31/2003 | WO2003061560A2 Replication competent dual-ad vectors for vaccine and immunotherapy applications |
| 07/31/2003 | WO2003061365A2 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof |
| 07/31/2003 | WO2003057698A3 Spiroazacyclic compounds as monoamine receptor modulators |
| 07/31/2003 | WO2003039460A3 Mitotic kinesin inhibitors |
| 07/31/2003 | WO2003035679A3 Molecules |
| 07/31/2003 | WO2003028696A3 Compositions for delivery of drug combinations |
| 07/31/2003 | WO2003020702A9 Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain |
| 07/31/2003 | WO2003010139A3 Antisense modulation of hormone-sensitive lipase expression |
| 07/31/2003 | WO2003005958A3 Hypertension associated transcription factors and uses therefor |
| 07/31/2003 | WO2003002596A3 Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders |
| 07/31/2003 | WO2002101005A3 A g-protein coupled receptor and uses therefor |
| 07/31/2003 | WO2002100408A3 Treating neuropathic/inflammatory pain by targeting a composition (e.g. zd7288) to hcn pacemaker channels |
| 07/31/2003 | WO2002086123A3 A human g-protein coupled receptor, hgprbmy11, expressed highly in heart and variants thereof |
| 07/31/2003 | WO2002064627A3 Crystallization of igf-1 |
| 07/31/2003 | WO2002062762A3 Potassium channel openers |
| 07/31/2003 | WO2002060892A8 Ethanolates of sodium-hydrogen exchanger type-1 inhibitor |
| 07/31/2003 | WO2002060875A8 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes |
| 07/31/2003 | WO2002060464A3 Compositions containing an active fraction isolated from hedyotis diffusae and methods of use |
| 07/31/2003 | WO2002030863A3 Ether compounds and compositions for cholesterol management and related uses |
| 07/31/2003 | WO2002029038A3 Novel proteins and nucleic acids encoding same and antibodies directed against these proteins |
| 07/31/2003 | WO2002018444A3 Erbb4 antagonists |
| 07/31/2003 | WO2002018361A3 Compounds having activity as inhibitors of cytochrome p450rai |
| 07/31/2003 | WO2001062298A9 Compositions and methods for treatment of angiogenesis in pathological lesions |
| 07/31/2003 | US20030144701 Method and system for terminating an atrial arrhythmia |
| 07/31/2003 | US20030144529 Treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula I Mitogen-activated protein kinases (MAP) is a family of proline- directed serine/threonine kinases that activate their |
| 07/31/2003 | US20030144507 Sulfonamide-containing heterocyclic compounds |
| 07/31/2003 | US20030144350 Modulating fatty acid or triglyceride accumulation by cells; treating obesity and metabolic disorders |
| 07/31/2003 | US20030144347 Method for treating autoimmune disease |
| 07/31/2003 | US20030144343 To treat and/or prevent hypertension, cardiac hypertrophy, cardiac insufficiency, coronary heart diseases such as angina pectoris, and endothelial dysfunction or endothelial damage as a consequence of atherosclerotic processes or diabetes |
| 07/31/2003 | US20030144340 By inhibiting fetal cardiac gene expression and interfering with sarcomeric organization |
| 07/31/2003 | US20030144337 Pyrazole-derived kinase inhibitors and uses thereof |
| 07/31/2003 | US20030144334 Cyclopentabenzofuran derivatives and their use |
| 07/31/2003 | US20030144332 Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals |
| 07/31/2003 | US20030144328 Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 07/31/2003 | US20030144326 Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| 07/31/2003 | US20030144316 Remedies |
| 07/31/2003 | US20030144311 Propanoic acid derivatives as intergrin receptor antagonists |
| 07/31/2003 | US20030144305 Novel compounds |
| 07/31/2003 | US20030144302 Process for making substituted pyrazoles |
| 07/31/2003 | US20030144300 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes |
| 07/31/2003 | US20030144298 Therapeutic combinations of antihypertensive and antiangiogenics agents |
| 07/31/2003 | US20030144295 A synergistic antiischemic mixture of a tissue plasminogen activator, e.g. alteplase, pamiteplase, and zonampanel(7-imidazol-1-yl-6-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin -1-yl acetic acid for strokes or cerebral infarctions |
| 07/31/2003 | US20030144293 N-alkyl-adamantyl triazinyl benzamide derivatives |
| 07/31/2003 | US20030144291 Substituted indan derivatives |
| 07/31/2003 | US20030144290 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives |
| 07/31/2003 | US20030144288 Sulfur compounds such as 4-fluoro-N-(4-methoxy-7-(tetrahydro-pyran-4-yl)-benzothiazol-2-yl) -benzamide, used as preferential adenosine receptor ligands for the prophylaxis of neurodegenerative disorders |
| 07/31/2003 | US20030144287 Heterocyclic amides such as N-(4-(2-(((methyl)amino)methyl)-1H-imidazol-1-yl)-2-fluorophenyl)-1-(3-amino-1,2-benzisoxazol-5-yl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide, used as anticoagulants; prophylaxis of cardiovascular disorders |
| 07/31/2003 | US20030144284 Heterocyclic imines such as 2-anilino-6-quinoxalinol, used to suppress cell proliferation, differentiation, chemotaxis and/or activation; prophylaxis of restinosis; anticarcinogenic agents |
| 07/31/2003 | US20030144279 5-Heterocyclo-pyrazoles |
| 07/31/2003 | US20030144274 Preferential enzyme inhibitors such as 3-(4-Methoxyphenyl)-prop-1-ynyl)-N-(4-carboxybenzyl)benzamide, used for prophylaxis of degenerative diseases including cancer and arthritis |
| 07/31/2003 | US20030144270 Neurokinin receptor antagonists comprising heterocyclic amides used as antiemetics, antidepressants and/or antitussive agents |
| 07/31/2003 | US20030144269 Administering an effective amount of vasopeptidase inhibitor such as omapatrilat or gemopatrilat for reducing hypertension |
| 07/31/2003 | US20030144268 Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors |
| 07/31/2003 | US20030144267 Novel compounds |
| 07/31/2003 | US20030144266 Pyrazolo-triazolo- pyrimidine, triazolo-triazolo-pyrimidine and imidazolo-triazolo-pyrimidine derivatives useful for the treatment of hypertension, inflammation, mast cell degranulation, cardiac hypoxia, and ischemia |
| 07/31/2003 | US20030144262 Heteroaryl and heterocyclic nitrogen ring containing hydrazide compounds useful for treating neurodegenerative disorderes |
| 07/31/2003 | US20030144261 A cyclic peptide useful for treating eating disorder and diabetes |
| 07/31/2003 | US20030144247 Obtained by reacting polyalkylene glycol or a reactive derivative, a phospholipid and a drug with each other to form covalent bonds to form a delivery substance |
| 07/31/2003 | US20030144240 Antisense strategy to modulate estrogen receptor response (ER alpha and/or ER beta) |
| 07/31/2003 | US20030144233 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides |
| 07/31/2003 | US20030144210 Treatment of neurologic and psychiatric disorders |
| 07/31/2003 | US20030144206 Combined use of a GLP-1 compound and modulator of diabetic late complications |
| 07/31/2003 | US20030144203 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 07/31/2003 | US20030144200 Novel forms of the angiogenic factor vascular endothelial cell growth factor: VEGF |
| 07/31/2003 | US20030144198 Increasing gastrointestinal absorption |
| 07/31/2003 | US20030144176 Methods and compositions relating to MEK5 and cardiac hypertrophy and dilated cardiomyopathy |
| 07/31/2003 | US20030143695 Novel polypeptide and dna thereof |
| 07/31/2003 | US20030143690 Peptides and proteins that effect protein phosphorylation; genetic engineered DNA; useful for therapy and diagnosis |
| 07/31/2003 | US20030143676 Receptor polypeptides and polynucleotides encoding such polypeptides; for treating a disorder characterized by an elevated level of osteopontin |
| 07/31/2003 | US20030143656 Drug screening compounds which inhibit rate of phosphorylation by kinase having hydrophobic pocket domain; surface plasmon resonance; fusion proteins; anticancer-/ antidiabetic agents |
| 07/31/2003 | US20030143626 Such as cyclin-dependent kinases and/or bax genes/proteins covalently linked to platform compound (thioredoxin); drug screening |
| 07/31/2003 | US20030143589 Drug metabolizing enzymes |
| 07/31/2003 | US20030143588 Phosphodiesterases |
| 07/31/2003 | US20030143304 Human and animal nutrition and dietary supplementation |
| 07/31/2003 | US20030143289 For therapy of cerebral vascular disease, including stroke, intracranial hemorrhage, intracranial infarction, and vascular dementia |
| 07/31/2003 | US20030143271 For therapy and prophylaxis of cyclooxygenase-2 mediated disorder and for providing cardioprotection |
| 07/31/2003 | US20030143246 Ganoderma lucidum spores for treatment of autoimmune diseases |
| 07/31/2003 | US20030143226 For therapy of arteriosclerosis, thrombocytopenia, kidneyd iseases, various types of inflammation such as myocardial ischemic reperfusion injury, inflammatory reactions after percutaneous transluminal coronary recanalization (PTCR)) |
| 07/31/2003 | US20030143223 Modulating the activity of one or more elements in the complement/lipid pathway |
| 07/31/2003 | US20030143209 For gene therapy of cancers or cardiovascular conditions |